

QUALISYS EXPANDS ITS MARKERLESS MOTION CAPTURE PORTFOLIO WITH PRISMA POSE - BUILT FOR BIOMECHANICS LABS

Gothenburg, Sweden - June 10, 2026 - Qualisys today introduced Prisma Pose, a new engine that integrates markerless skeletal tracking directly into Qualisys Track Manager (QTM), eliminating the need for third-party software for biomechanics laboratories. Prisma Pose is proprietary Qualisys technology that expands the company's markerless portfolio with an offering that covers the full spectrum of needs across sport, clinical, and research.

Prisma Pose is designed to give biomechanics laboratories a practical and accessible markerless tracking solution, with no need for additional software vendors or hardware investments. Alongside OnTraq, purpose-built for performance analysis in elite sport, and Qualisys' partnership with Theia for laboratories with more extensive requirements, Qualisys now offers a complete suite of markerless solutions, tailored to the needs and ambitions of each organization.

"This is a significant step in our platform strategy. With our existing portfolio, and now with Prisma Pose, we have a markerless solution that responds to every need within human research and analysis", says Ingemar Pettersson, CEO, Qualisys.

Eliminating Complexity in the Lab

Running markerless motion capture in a QTM-based lab today typically requires a second software stack - a separate license and additional steps to align markerless output with optical, force plate, and EMG data. Prisma Pose brings the full markerless processing chain inside QTM, with automatic synchronization across all data streams and direct integration into existing Qualisys analysis modules and Web Reports. Support is covered under existing Qualisys plans.

"Prisma Pose engine integrated in QTM also powers OnTraq. Two years of real-world deployment of OnTraq have sharpened our understanding of what biomechanics labs need from markerless capture, and that experience is built directly into Prisma Pose," says Magnus Berlander, CTO, Qualisys.

Launch Capabilities

Prisma Pose is validated for the most common biomechanical assessment tasks - making it well suited for labs conducting routine movement assessments, rehabilitation research, and sports science studies. Biomechanics labs using QTM can access Prisma Pose as an add-on license in the last quarter of 2026 when it will be launched.

Qualisys will showcase QTM with Prisma Pose at the World Congress of Biomechanics and the International Society of Biomechanics in Sports conference this summer, as well as at several regional events during the fall. Customers and research institutions interested in early access can contact their local Qualisys representative or visit qualisys.com.

A Growing Market Opportunity

Demand for markerless capture is growing as labs seek to reduce participant burden and reach populations where marker attachment is not practical. Unlike competitors who license third-party markerless software, Qualisys has developed its own proprietary engine, giving the company full control over its roadmap and a strong and independent position in the markerless segment. For Qualisys, Prisma Pose represents incremental add-on license revenue from customers who have already made the primary hardware investment.

With OnTraq, Prisma Pose, and through the long-standing Theia partnership, Qualisys offers a differentiated product portfolio across the full markerless spectrum - one of the fastest-growing segments in human movement research.

For more information please contact:

Ingemar Pettersson, CEO

E-mail: Ingemar.Pettersson@qualisys.se

Magnus Berlander, CTO

E-mail: Magnus.Berlander@qualisys.com

About Qualisys Holding AB (publ)

Qualisys is a leading provider of motion capture technology and has a long history of supplying research, engineering, entertainment, and sports facilities with high-end camera systems and expertise in capturing and analyzing movements. Qualisys offers a wide range of products and services with its headquarter in Gothenburg, Sweden, and operations in Chicago, Singapore, Shanghai and Delhi. Qualisys is certified according to ISO 9001:2015 and ISO 27001:2023. The clinical products are compliant with Medical Device Directive 93/42/EEC and have FDA clearance (K171547).

Qualisys is listed on Nasdaq First North Premier Growth Market. The company's Certified Adviser is Svensk Kapitalmarknadsgranskning AB.

Image Attachments

PP Manual Image